Eleven Biotherapeutics, a Cambridge, MA-based biopharmaceutical company focused on translating breakthrough discoveries from science and medicine to engineer and develop innovative protein-based therapeutics, has completed a $35m Series A financing.
The round was co-led by Flagship Ventures and Third Rock Ventures.
Proceeds from the financing will be used to build the research and development and business development teams for Eleven Biotherapeutics, in addition to advancing the company’s portfolio of engineered proteins through clinical proof of concept.
FinSMEs
17/02/2010